Glance of Some Unprecedented Biotechnologies
- Novel Camelid Therapeutics and Antidotes
Applied Bio Research has a comprehensive study that serves as a basis for establishing a pioneering scientific development, unprecedented in the world, by using camelid IgG and converting camel waste, such as urine and camel hump, into billions of dollars annually.
The unique camel heteropolymer immuno-system that can be developed uses camelid IgG antibodies chemically joined together, like biological double-sided tape. One of these antibodies sticks to the target to be removed (such as the bacterial toxin); the other binds to a receptor found on human red blood cells. The red blood cells then carry the pathogen to the liver for destruction and returns unharmed to the normal blood circulation. This whole process happens within minutes. In this case, camelid IgG works like a temporary vaccine in that it confers an instant but temporary state of immunity to pathogens that are carried in the bloodstream, whether bacterial or viral.
Unlike vaccines, antibiotics and antivirals, the camelid IgG can be programmed to be active against anything that circulates in the bloodstream – bacteria, toxins, and viruses.
- Camelid IgG subclass 2 and 3 Treats and Diagnoses the Novel Coronavirus (COVID-19)
Multiple companies and universities around the world have been exploring the use of antibodies to treat coronavirus. Encouragingly, Dr. Sabah Jassim discovered that the camelid antibody (IgG subclass 2 and 3) present in both camel’s milk and their urine belongs to a class called ‘neutralizing’ or binding antibodies (http://www.sumobrain.com/patents/wipo/Camelid-antibodies-use-in-compositions/WO2011104565.html). They can fully and specifically bind to the part of the virus that fits like a lock and key with parts of human cells. Therefore, the general idea of Applied Bio Research is that neutralizing camelid antibodies (IgG subclass 2 and 3) also has the potential to act like a ‘temporary vaccines’, preventing coronavirus infection in people. Camelid IgG could act as a ‘protective shield’ for human cells, preventing the virus that causes COVID-19 from entering them. It blocks the virus from its primary doorway, a receptor on the surface of human cells, the ACE2 receptor. When the antibody prevents a virus from entering a human cell, the virus cannot survive. This will be extremely important for health care around the world. Applied Bio Research believes that Camelid IgG can be developed further to cure the following illnesses: COVID-19, HCV, HIV, Tuberculosis, Cancer, Autism, Allergies, Crohn’s disease, Autoimmune diseases, and many others.
More information regarding the camelid IgG technology can be found at:
Jassim SAA, et al. 2011 WIPO Patent Application WO/2011/104565. Camelid antibodies for use in compositions and methods for the treatment of cancer
http://www.sumobrain.com/patents/wipo/Camelid-antibodies-use-in-compositions/WO2011104565.html)
Jassim S. A. A . et al. 2001. The desert ship: heritage and science.Biologist (UK) 48 (6), 268-272.http://www.ncbi.nlm.nih.gov/pubmed/11740078
- Herbal/Plant Preparations prevents and cures severe acute respiratory syndrome coronavirus 2.
Applied Bio Research has recently filed a US patent application for a novel phyto formula that can treat patients and prevent viral infections. The invention identified a potential herbal preparation remedy that can inhibit the infection process. This may lead to a new approach in the design of novel antiviral drugs, noting that it could be used to develop new herbal drugs for a variety of other human viral diseases including the novel SARS-CoV-2 (COVID-19), common cold virus, influenza viruses, rotaviruses, and the like.
More information regarding phyto anti-viral technology can be found at:
Jassim SAA et al (1998) Antiviral or antifungal composition comprising an extract of pomegranate rind or other plants and method of use. US5840308A. https://patents.google.com/patent/US5840308A/en; https://patentimages.storage.googleapis.com/30/ce/d8/6285a2003c1bfe/US5840308.pdf.
Jassim SAA (1999) Antiviral agent. WO/1999/00853 ANTIVIRAL AGENT; EP 0 896 792 A1. http://www.freepatentsonline.com/EP0896792.pdf; https://patentscope.wipo.int/search/en/detail.jsf?docId=WO1999008536
Jassim SAA and Naji MA (2003) Novel antiviral agents: A medicinal plant perspective. Journal of Applied Microbiology 95:412-427. https://www.ncbi.nlm.nih.gov/pubmed/12911688.
Jassim SAA (2005) Novel phyto-anti-HIV drugs: A cause for optimism, Biologist 52 (5), 268-272. http://connection.ebscohost.com/c/articles/18876946/novel-phyto-anti-hiv-drugs-cause-optimism.
Jassim SAA and Naji MA (2007) In vitro evaluation of the antiviral activity of an extract of date palm (Phoenix dactylifera L.) pits on a pseudomonas phage. eCAM 7(1)57–62 http://downloads.hindawi.com/journals/ecam/2010/816839.pdf.